TITLE

Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)

AUTHOR(S)
Pappas, Peter G.; Alexander, Barbara D.; Andes, David R.; Hadley, Susan; Kauffman, Carol A.; Freifeld, Alison; Anaissie, Elias J.; Brumble, Lisa M.; Herwaldt, Loreen; Ito, James; Kontoyiannis, Dimitrios P.; Lyon, G. Marshall; Marr, Kieren A.; Morrison, Vicki A.; Park, Benjamin J.; Patterson, Thomas F.; Perl, Trish M.; Oster, Robert A.; Schuster, Mindy G.; Walker, Randall
PUB. DATE
April 2010
SOURCE
Clinical Infectious Diseases;4/15/2010, Vol. 50 Issue 8, p1101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among organ transplant recipients. Multicenter prospective surveillance data to determine disease burden and secular trends are lacking. Methods. The Transplant-Associated Infection Surveillance Network (TRANSNET) is a consortium of 23 US transplant centers, including 15 that contributed to the organ transplant recipient dataset. We prospectively identified IFIs among organ transplant recipients from March, 2001 through March, 2006 at these sites. To explore trends, we calculated the 12-month cumulative incidence among 9 sequential cohorts. Results. During the surveillance period, 1208 IFIs were identified among 1063 organ transplant recipients. The most common IFIs were invasive candidiasis (53%), invasive aspergillosis (19%), cryptococcosis (8%), non- Aspergillus molds (8%), endemic fungi (5%), and zygomycosis (2%). Median time to onset of candidiasis, aspergillosis, and cryptococcosis was 103, 184, and 575 days, respectively. Among a cohort of 16,808 patients who underwent transplantation between March 2001 and September 2005 and were followed through March 2006, a total of 729 IFIs were reported among 633 persons. One-year cumulative incidences of the first IFI were 11.6%, 8.6%, 4.7%, 4.0%, 3.4%, and 1.3% for small bowel, lung, liver, heart, pancreas, and kidney transplant recipients, respectively. One-year incidence was highest for invasive candidiasis (1.95%) and aspergillosis (0.65%). Trend analysis showed a slight increase in cumulative incidence from 2002 to 2005. Conclusions. We detected a slight increase in IFIs during the surveillance period. These data provide important insights into the timing and incidence of IFIs among organ transplant recipients, which can help to focus effective prevention and treatment strategies.
ACCESSION #
49097028

 

Related Articles

  • Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Kontoyiannis, Dimitrios P.; Marr, Kieren A.; Park, Benjamin J.; Alexander, Barbara D.; Anaissie, Elias J.; Walsh, Thomas J.; Ito, James; Andes, David R.; Baddley, John W.; Brown, Janice M.; Brumble, Lisa M.; Freifeld, Alison G.; Hadley, Susan; Herwaldt, Loreen A.; Kauffman, Carol A.; Knapp, Katherine; Lyon, G. Marshall; Morrison, Vicki A.; Papanicolaou, Genovefa; Patterson, Thomas F. // Clinical Infectious Diseases;4/15/2010, Vol. 50 Issue 8, p1091 

    Background. The incidence and epidemiology of invasive fungal infections (IFIs), a leading cause of death among hematopoeitic stem cell transplant (HSCT) recipients, are derived mainly from single-institution retrospective studies. Methods. The Transplant Associated Infections Surveillance...

  • Invasive mycoses in children receiving hemopoietic SCT. Castagnol, E.; Faraci, M.; Moroni, C.; Bandettini, R.; Granata, C.; Caruso, S.; Bagnasco, F.; Caviglia, I.; Malgorzata, M.; Furfaro, E.; Natalizia, A. R.; de Fazio, V.; Morreale, G.; Lanino, E.; Haupt, R.; Dini, G.; Viscoli, C. // Bone Marrow Transplantation;Jun2008 Supplement, Vol. 41, pS107 

    Invasive mycoses represent a rare but severe complication following hemopoietic SCT (HSCT) in children. Their incidence is related to the type of donor, being higher after allogeneic transplant, especially from alternative donors. Moreover, the incidence of invasive mycoses varies in the...

  • Transfusion Associated Graft Versus Host Disease. Naveen, Kikkeri Narayanshetty; Athanker, Sharatchandra B.; Rajoor, Umesh; Sindhoor, Jayaraj // Indian Journal of Dermatology;May/Jun2015, Vol. 60 Issue 3, following p320 

    The article describes the case of a patient with transfusion-associated graft-versus-host disease (TA-GVHD). It discusses the clinical characteristics of TA-GVHD, symptoms experienced by the patient, the patient's medical history, results of the patient's medical examinations and treatments...

  • HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. Chen, Y.; Liu, K.; Xu, L.; Chen, H.; Liu, D.; Zhang, X.; Shi, H.; Han, W.; Wang, Y.; Zhao, T.; Wang, J.; Huang, X. // Bone Marrow Transplantation;Aug2010, Vol. 45 Issue 8, p1333 

    Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized...

  • Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation. Lorenz, Fryderyk; Marklund, Stefan; Werner, Mårten; Palmqvist, Richard; Wahlin, Björn Engelbrekt; Wahlin, Anders // Scientific Reports;1/23/2015, p7920 

    The diagnosis of gastrointestinal graft versus host disease (GI-GVHD) is based on clinical symptoms and histological findings. In clinical practice, it is often difficult to decide whether abdominal symptoms in an allogeneic transplant recipient are caused by GVHD or other disorders. Endoscopic...

  • Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. Lehrnbecher, T.; Frank, C.; Engels, K. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p154 

    This study provides an insight into the epidemiology of invasive fungal infections (IFI) in a German population using post mortem examinations. The prevalence of IFI was 8.2%, and predisposing conditions included hematological malignancies, AIDS, solid tumors, and organ transplantation. The most...

  • Posaconazole demonstrates efficacy for prophylaxis of fungal infections in certain patients.  // Formulary;Mar2007, Vol. 42 Issue 3, p184 

    The article reports on the efficacy of posaconazole for treating patients with prophylaxis of fungal infections. This has been demonstrated by two randomized and controlled trials indicating that posaconazole considered a primary option for these patients with severe graft versus host disease...

  • An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Dignan, F. L.; Evans, S. O.; Ethell, M. E.; Shaw, B. E.; Davies, F. E.; Dearden, C. E.; Treleaven, J. G.; Riley, U. B. G.; Morgan, G. J.; Potter, M. N. // Bone Marrow Transplantation;Jul2009, Vol. 44 Issue 1, p51 

    Empirical antifungal therapy is frequently used in allogeneic transplant patients who have persistent febrile neutropenia and can be associated with high cost, toxicity and breakthrough infections. There are limited reports of strategies for early diagnosis of invasive fungal infection (IFI)...

  • Patient develops extensive eruption, mild Nausea. Levine, Norman // Dermatology Times;Jul99, Vol. 20 Issue 7, p3 

    Describes the characteristics and skin manifestations of graft versus host disease (GVH) in a patient with a history of bone marrow transplant. Types of GVH; Absence of therapeutic alternative; Reduction on the severity of skin changes by photochemotherapy; Immunosuppressive agents as...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics